Prenetics Global Ltd
Prenetics Global Limited, a health sciences company, focuses on advancing consumer health in Hong Kong, the United States, and internationally. It sells health and wellness products under the IM8 brand name; and provides fulfillment and distribution services for sports nutrition products under the Europa brand. The company is also involved in the operation of CircleDNA, a consumer genetic testing… Read more
Prenetics Global Ltd (PRE) - Net Assets
Latest net assets as of September 2025: $161.20 Million USD
Based on the latest financial reports, Prenetics Global Ltd (PRE) has net assets worth $161.20 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($196.51 Million) and total liabilities ($35.30 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $161.20 Million |
| % of Total Assets | 82.03% |
| Annual Growth Rate | -9.89% |
| 5-Year Change | 452.6% |
| 10-Year Change | -97.53% |
| Growth Volatility | 307.0 |
Prenetics Global Ltd - Net Assets Trend (2000–2024)
This chart illustrates how Prenetics Global Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Prenetics Global Ltd (2000–2024)
The table below shows the annual net assets of Prenetics Global Ltd from 2000 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $171.35 Million | -18.47% |
| 2023-12-31 | $210.16 Million | -13.68% |
| 2022-12-31 | $243.46 Million | +160.73% |
| 2021-12-31 | $-400.89 Million | -1392.92% |
| 2020-12-31 | $31.01 Million | +83.99% |
| 2019-12-31 | $16.85 Million | -99.76% |
| 2015-12-31 | $6.90 Billion | -2.84% |
| 2014-12-31 | $7.10 Billion | +5.00% |
| 2013-12-31 | $6.77 Billion | -2.41% |
| 2012-12-31 | $6.93 Billion | +7.20% |
| 2011-12-31 | $6.47 Billion | -10.26% |
| 2010-12-31 | $7.21 Billion | -5.74% |
| 2009-12-31 | $7.65 Billion | +82.08% |
| 2008-12-31 | $4.20 Billion | -2.83% |
| 2007-12-31 | $4.32 Billion | +14.15% |
| 2006-12-31 | $3.79 Billion | +22.41% |
| 2005-12-31 | $3.09 Billion | -7.73% |
| 2004-12-31 | $3.35 Billion | +29.20% |
| 2003-12-31 | $2.59 Billion | +24.90% |
| 2002-12-31 | $2.08 Billion | +18.82% |
| 2001-12-31 | $1.75 Billion | -16.20% |
| 2000-12-31 | $2.09 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Prenetics Global Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 145.6% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $19.00K | 0.01% |
| Other Comprehensive Income | $-169.25 Million | -99.33% |
| Other Components | $856.69 Million | 502.79% |
| Total Equity | $170.39 Million | 100.00% |
Prenetics Global Ltd Competitors by Market Cap
The table below lists competitors of Prenetics Global Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jiangyin Pivot Automotive Products Co. Ltd.
SHE:301181
|
$219.14 Million |
|
Changzhou Galaxy Century Microelectronics Co Ltd
SHG:688689
|
$219.19 Million |
|
Reysas Gayrimenkul Yatirim Ortakligi A.S.
PINK:RYGYF
|
$219.29 Million |
|
GurSel Turizm Tasimacilik Ve Servis Ticaret AS
IS:GRSEL
|
$219.32 Million |
|
Ningbo Lehui International Engineering Equipment Co Ltd Class A
SHG:603076
|
$219.13 Million |
|
Hangzhou Kaierda Welding Robot Co Ltd
SHG:688255
|
$219.11 Million |
|
Junhe Pumps Holding Co Ltd
SHG:603617
|
$219.09 Million |
|
Guangdong Deerma Technology Co. Ltd. A
SHE:301332
|
$219.08 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Prenetics Global Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 206,359,000 to 170,389,000, a change of -35,970,000 (-17.4%).
- Net loss of 46,304,000 reduced equity.
- Share repurchases of 577,000 reduced equity.
- Other comprehensive income increased equity by 6,779,000.
- Other factors increased equity by 4,132,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-46.30 Million | -27.18% |
| Share Repurchases | $577.00K | -0.34% |
| Other Comprehensive Income | $6.78 Million | +3.98% |
| Other Changes | $4.13 Million | +2.43% |
| Total Change | $- | -17.43% |
Book Value vs Market Value Analysis
This analysis compares Prenetics Global Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.53x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.34x to 1.53x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-12-31 | $60.94 | $20.46 | x |
| 2005-12-31 | $56.23 | $20.46 | x |
| 2006-12-31 | $65.27 | $20.46 | x |
| 2007-12-31 | $74.51 | $20.46 | x |
| 2008-12-31 | $74.98 | $20.46 | x |
| 2009-12-31 | $119.46 | $20.46 | x |
| 2010-12-31 | $92.40 | $20.46 | x |
| 2011-12-31 | $95.11 | $20.46 | x |
| 2012-12-31 | $108.34 | $20.46 | x |
| 2013-12-31 | $119.81 | $20.46 | x |
| 2014-12-31 | $0.00 | $20.46 | x |
| 2015-12-31 | $0.00 | $20.46 | x |
| 2019-12-31 | $2.29 | $20.46 | x |
| 2020-12-31 | $4.20 | $20.46 | x |
| 2021-12-31 | $-108.35 | $20.46 | x |
| 2022-12-31 | $46.76 | $20.46 | x |
| 2023-12-31 | $18.35 | $20.46 | x |
| 2024-12-31 | $13.41 | $20.46 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Prenetics Global Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -27.18%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -151.22%
- • Asset Turnover: 0.14x
- • Equity Multiplier: 1.25x
- Recent ROE (-27.18%) is below the historical average (-5.39%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | 6.82% | 9.33% | 0.25x | 2.92x | $-66.29 Million |
| 2002 | 9.16% | 7.13% | 0.31x | 4.21x | $-17.42 Million |
| 2003 | 18.03% | 12.08% | 0.36x | 4.20x | $208.24 Million |
| 2004 | 14.69% | 11.80% | 0.33x | 3.73x | $157.17 Million |
| 2006 | 19.79% | 17.89% | 0.28x | 3.95x | $370.75 Million |
| 2007 | 16.61% | 17.29% | 0.26x | 3.71x | $285.66 Million |
| 2008 | 1.11% | 1.16% | 0.25x | 3.88x | $-373.34 Million |
| 2009 | 20.10% | 28.81% | 0.22x | 3.10x | $772.28 Million |
| 2010 | 11.83% | 14.44% | 0.25x | 3.24x | $131.86 Million |
| 2012 | 16.36% | 20.40% | 0.24x | 3.31x | $441.16 Million |
| 2013 | 9.90% | 11.88% | 0.24x | 3.43x | $-6.95 Million |
| 2014 | 14.97% | 16.29% | 0.29x | 3.16x | $350.08 Million |
| 2015 | 1.51% | 1.91% | 0.26x | 3.10x | $-585.67 Million |
| 2019 | -119.14% | -218.15% | 0.31x | 1.76x | $-21.83 Million |
| 2020 | -6.24% | -2.98% | 0.83x | 2.54x | $-5.05 Million |
| 2021 | 0.00% | -1388.44% | 0.08x | 0.00x | $-133.93 Million |
| 2022 | -80.34% | -1446.78% | 0.04x | 1.32x | $-214.16 Million |
| 2023 | -30.40% | -288.48% | 0.09x | 1.23x | $-83.36 Million |
| 2024 | -27.18% | -151.22% | 0.14x | 1.25x | $-63.34 Million |
Industry Comparison
This section compares Prenetics Global Ltd's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $867,957,363
- Average return on equity (ROE) among peers: -141.01%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Prenetics Global Ltd (PRE) | $161.20 Million | 6.82% | 0.22x | $219.13 Million |
| Agilent Technologies Inc (A) | $4.57 Billion | 6.91% | 0.87x | $31.45 Billion |
| Amer Bio Medica (ABMC) | $-944.00K | 0.00% | 0.00x | $3.55K |
| ADCNF (ADCNF) | $612.34 Million | 111.18% | 6.93x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.64 Million |
| ANGLE plc (ANPCF) | $18.44 Million | -77.14% | 0.38x | $34.42 Million |
| SeqLL Inc. (ATLN) | $4.37 Million | -93.77% | 0.93x | $36.19K |
| Avricore Health Inc (AVCRF) | $3.35 Million | -65.62% | 0.06x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $4.67 Million | -153.12% | 0.85x | $664.47K |
| Biodesix Inc (BDSX) | $4.58 Million | -1138.56% | 20.64x | $48.86 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $5.08 Million |